Loading...
A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
BACKGROUND: We explored the therapeutic effects of dinaciclib, a cyclin-dependent kinase (CDK) inhibitor, in the treatment of thyroid cancer. MATERIALS AND METHODS: Seven cell lines originating from three pathologic types of thyroid cancer (papillary, follicular and anaplastic) were studied. The cyt...
Na minha lista:
| Udgivet i: | PLoS One |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5312924/ https://ncbi.nlm.nih.gov/pubmed/28207834 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0172315 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|